Sodium Bicarbonate (sodium bicarbonate)

Where it stands

Sodium Bicarbonate (sodium bicarbonate) from Amneal is approved in the US. The records give an FDA approval date of 2026-07-09 under NDA220790. The dosage form is a solution, and the approval is classed as a new formulation or manufacturer.

The records do not give a therapeutic area or an indication. This analysis therefore cannot describe the labeled use, patient population or dose, and the FDA label should be checked for those.

The records also show a separate FDA approval on 2026-08-14 for Sodium Bicarbonate from Baxter Healthcare Corp under NDA218524. It carries the same classification and is also a solution. It is a different sponsor and a different application, so it should not be read as an extension of Amneal's approval. A further US record for the same substance is listed as approved, with no detail given.

Regulatory pathway and designations

This is a US FDA approval, so there is no CHMP opinion. The record shows none, and EU procedures do not apply to it. The only designation recorded is "New formulation or manufacturer." It describes the kind of application and is not a special regulatory status.

In general, a classification like this indicates the product is not a novel active ingredient. It is a new formulation, presentation or source of an already-known substance. Such products do not normally carry the novelty-based incentives or expedited-program designations seen with new molecular entities. The records show no orphan, priority review, breakthrough or similar designations.

Amneal's and Baxter's approvals sit under separate NDAs, 220790 and 218524. The records do not say which regulatory route either NDA used, such as a full application or a 505(b)(2) application relying partly on existing literature or prior findings. They do not describe the supporting data package or any reference product.

Safety and pharmacovigilance

The records contain no safety information, such as labeled warnings, postmarketing requirements, REMS or adverse event data, so no safety assessment can be made from them.

What to watch

The first step is to retrieve the approved labeling and approval letter for NDA220790 from FDA sources. They should confirm the indication, strength, container presentation and any conditions of approval. The records leave these blank.

Competitively, at least two sponsors, Amneal and Baxter, now hold separate approvals for sodium bicarbonate solution, and another US record for the substance is listed as approved. Business-development and regulatory teams should check how the products differ in presentation or labeling and whether any therapeutic-equivalence ratings have been assigned. The records do not cover launch timing, supply or market position.